Enveric Biosciences Inc (ENVB) - News Archive

Cambridge, Mass. - Enveric Biosciences Patents Pathways to Mental Health Innovation In the dynamic intersection of biotechnology and psychiatry, Enveric Biosciences (NASDAQ: ENVB) stands as a forward-thinking entity, pi...

Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology firm based in Cambridge, Massachusetts, has successfully closed the exercise of certain outstanding warrants, resulting in gross proceeds of $2.2 million. This f...

In an era marked by significant advancements in the field of medicinal chemistry, the ability to innovate bioproduction methods stands as a beacon of hope for drug discovery, particularly in the domain of neuropsychiatr...

Enveric Biosciences: Pioneering Neuroplastogenic Therapeutics Amidst a Strategic Move to Cambridge In a strategic pivot aimed at enhancing its operational capacity and innovation potential, Enveric Biosciences (NASDAQ:...

Enveric Biosciences Advances with EB-003 Amidst Financial Challenges Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company based in Cambridge, Massachusetts, is making strides in the realm of neuropsychiatri...

Enveric Biosciences Inc. (NASDAQ: ENVB), a biotechnology firm concentrating on pioneering neuroplastogenic small molecule therapeutics targeting psychiatric and neurological conditions, has recently made significant pro...

Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology firm rooted in Cambridge, Massachusetts, has recently made significant strides in its mission to develop innovative small-molecule therapeutics aimed at com...

In a significant step towards revolutionizing the treatment landscape for mental health disorders, Enveric Biosciences (NASDAQ: ENVB) has received a U.S. patent for its EVM401 series of compounds. This development signa...

: Enveric Biosciences, a biotechnology company focused on innovative small-molecule therapeutics targeting neuroplasticity, has made significant strides in the development of its lead drug candidate, EB-003. Recent anno...

Enveric Biosciences: Navigating A New Patent Milestone Amidst Market Challenges In a landscape characterised by dynamic shifts and competitive forces, Enveric Biosciences (NASDAQ: ENVB), a Cambridge-based biotechnology...

Enveric Biosciences’ EB-003 Exhibits Promising Preclinical Results in Oral Bioavailability and Brain Penetration Paving the Path for Next-Generation Neuroplastogen TherapeuticsRecent advancements in biotechnology have p...

In a market increasingly focused on mental health solutions, Enveric Biosciences (NASDAQ: ENVB), a leading biotechnology firm headquartered in Cambridge, Massachusetts, has reported its financial and operational results...

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results CAMBRIDGE, Mass. Enveric Biosciences (NASDAQ: ENVB) continues to make significant strides in the biotechnology sector, particularly in devel...

Enveric Biosciences Propels Forward with Strategic Licensing Deal and Patent Expansion amid Promising Q3 Results Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company focused on developing innovative neuropl...

Enveric Biosciences Expands Patent Protection, Advancing Neuropsychiatric Innovation CAMBRIDGE, Mass. Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology company focused on the development of innovative neuro...

Enveric Biosciences Unveils Promising Preclinical Data for Lead Therapeutic Candidate EB-003Enveric Biosciences, a biotechnology company that focuses on developing novel neuroplastogenic small-molecule therapeutics, rec...

CAMBRIDGE, Mass. In a significant stride towards alleviating the suffering of patients undergoing radiation therapy, Enveric Biosciences (NASDAQ: ENVB), a pioneer in the field of biotechnology dedicated to the developme...

Enveric Biosciences Sharpen Focus on Neuroplastogenic Therapies with New Lead Candidate EB-003Enveric Biosciences (NASDAQ: ENVB), the Cambridge-based biotechnology innovator, recently announced a pivotal strategic shift...

Enveric Biosciences Expands its Portfolio with Out-Licensing of Psilocin Prodrug Candidate and Sale of Cancer-Related Patent PortfolioEnveric Biosciences, a biotechnology company specializing in the development of neuro...

In an exciting reveal that could reshape the future of cancer treatment, Enveric Biosciences Inc. (NASDAQ: ENVB), a leading biotech firm primarily specializing in the development of innovative neuroplastogenic therapies...